In addition, NPRL2 was found to be significantly upregulated in docetaxel-resistant prostate cancer cells and associated with decreased mTOR signaling and elevated autophagy; depleting NPRL2 in these cells increases sensitivity to docetaxel by inducing apoptosis [16]. Here, NPRL2 is linked to prostate carcinoma.